Cridanimod
(Synonyms: 吖啶酮乙酸) 目录号 : GC38648
An inducer of type I interferon production
Cas No.:38609-97-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cridanimod is an inducer of type I interferon (IFN) production.1,2 It induces IRF3 phosphorylation, IFN-β production, and NF-κB activation in wild-type, but not in stimulator of interferon genes (STING) mutant, murine macrophages.1 In vivo, cridanimod (112-1,792 mg/kg) increases plasma levels of IFN in weanling and adult mice.2 Cridanimod inhibits viral infection in mouse models of Semliki forest, coxsackie B1, Columbia SK, herpes, and pseudorabies viruses with protective doses (PD50s) ranging from 17-320 mg/kg.3 It increases uterine expression of estrogen and progesterone receptors in ovariectomized rats.4 Cridanimod also reverses tamoxifen-induced decreases in progesterone receptor expression in young rats.
1.Cavlar, T., Deimling, T., Ablasser, A., et al.Species-specific detection of the antiviral small-molecule compound CMA by STINGEMBO J.32(10)1440-1450(2013) 2.Taylor, J.L., Schoenherr, C.K., and Grossberg, S.E.High-yield interferon induction by 10-carboxymethyl-9-acridanone in mice and hamstersAntimicrob. Agents Chemother.18(1)20-26(1980) 3.Kramer, M.J., Cleeland, R., and Grunberg, E.Antiviral activity of 10-carboxymethyl-9-acridanoneAntimicrob. Agents Chemother.9(2)233-238(1976) 4.Surkov, K.G., Tsyrlina, E.V., Konstantinova, M.M., et al.Neovir, an interferon inductor, modifies expression of steroid hormone receptors in hormone-dependent tissues and restores sensitivity to tamoxifen in patients with inoperable breast cancerVopr. Onkol.42(6)28-32(1996)
| Cas No. | 38609-97-1 | SDF | |
| 别名 | 吖啶酮乙酸 | ||
| Canonical SMILES | O=C(O)CN(C1=C2C=CC=C1)C3=CC=CC=C3C2=O | ||
| 分子式 | C15H11NO3 | 分子量 | 253.26 |
| 溶解度 | DMSO: 125 mg/mL (493.56 mM); Water: < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9485 mL | 19.7426 mL | 39.4851 mL |
| 5 mM | 0.7897 mL | 3.9485 mL | 7.897 mL |
| 10 mM | 0.3949 mL | 1.9743 mL | 3.9485 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Tilorone and Cridanimod Protect Mice and Show Antiviral Activity in Rats despite Absence of the Interferon-Inducing Effect in Rats
Pharmaceuticals (Basel) 2022 May 17;15(5):617.PMID:35631443DOI:10.3390/ph15050617.
The synthetic compounds, Tilorone and Cridanimod, have the antiviral activity which initially had been ascribed to the capacity to induce interferon. Both drugs induce interferon in mice but not in humans. This study investigates whether these compounds have the antiviral activity in mice and rats since rats more closely resemble the human response. Viral-infection models were created in CD-1 mice and Wistar rats. Three strains of Venezuelan equine encephalitis virus were tested for the performance in these models. One virus strain is the molecularly cloned attenuated vaccine. The second strain has major virulence determinants converted to the wild-type state which are present in virulent strains. The third virus has wild-type virulence determinants, and in addition, is engineered to express green fluorescent protein. Experimentally infected animals received Tilorone or Cridanimod, and their treatment was equivalent to the pharmacopoeia-recomended human treatment regimen. Tilorone and Cridanimod show the antiviral activity in mice and rats and protect the mice from death. In rats, both drugs diminish the viremia. These drugs do not induce interferon-alpha or interferon-beta in rats. The presented observations allow postulating the existence of an interferon-independent and species-independent mechanism of action.